RecombinantOTOR, Human

Otoraplin (OTOR) is a cytokine first identified in 2000 and encodes a small protein of 128 amino acids with an SH3 domain. OTOR is a homologue to CD-RAP/MIA and contains a hydrophobic N-terminal region as a signal peptide, which indicates that OTOR is mainly secreted. Researchers found that high expression of OTOR is only seen in the cochlea, demonstrating its importance in hearing. Indeed, loss of the gene produces cochlear dysfunction and otosclerosis, a hearing disorder involving the bony tissue of the ear. OTOR exerts an influence on the surrounding otic capsule and functions in the extracellular matrix of the membranous portion of the cochlea. Recombinant human Otoraplin (rhOTOR) produced in E.coli is a single non-glycosylated polypeptide chain containing 112 amino acids. rhOTOR has a molecular mass of 12.7 kDa analyzed by reducing SDS-PAGE and is obtained by proprietary chromatographic techniques at GenScript.

Product Specifications

Product Name Alternative

Otoraplin, Fibrocyte-derived protein, Melanoma inhibitory activity-like protein, OTOR, MIAL, FDP, MIAL1

Source

Escherichia coli.

Endotoxin

< 0.2 EU/μg, determined by LAL method.

Purity

> 95% by SDS-PAGE analysis.

Bioactivity

Data not available.

Form

Lyophilized after extensive dialysis against PBS.

Molecular Weight

12.7 kDa, observed by reducing SDS-PAGE.

Storage Conditions

Lyophilized recombinant human Otoraplin (rhOTOR) remains stable up to 6 months at -80°C from date of receipt. Upon reconstitution, rhOTOR remains stable up to 2 weeks at 4°C or up to 3 months at -20°C.